
Exai Bio is a pioneering company in the field of liquid biopsy, utilizing a next-generation RNA-based platform combined with artificial intelligence to provide actionable insights into cancer biology. Their innovative approach allows for early and accurate cancer detection through simple blood draws, aiming to transform cancer diagnostics and treatment. With a strong foundation in research and collaboration with biopharma and healthcare systems, Exai Bio is positioned to lead advancements in personalized medicine and improve patient outcomes.

Exai Bio is a pioneering company in the field of liquid biopsy, utilizing a next-generation RNA-based platform combined with artificial intelligence to provide actionable insights into cancer biology. Their innovative approach allows for early and accurate cancer detection through simple blood draws, aiming to transform cancer diagnostics and treatment. With a strong foundation in research and collaboration with biopharma and healthcare systems, Exai Bio is positioned to lead advancements in personalized medicine and improve patient outcomes.
Founded: 2021
Headquarters: Palo Alto, California
Technology: RNA-based liquid biopsy + AI (oncRNA profiling)
Series A: $67.5M (Dec 9, 2021)
Team size: Approximately 23 employees
Early cancer detection, diagnostics, and disease monitoring
2021
Biotechnology
$67,500,000
Two Sigma Ventures participated
“Series A led by venture investors Section 32 and Casdin Capital with participation from Two Sigma Ventures”